Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Our study investigated the immunomodulatory effects of sunitinib to rationally design combinational platforms with immunotherapies for the treatment of solid tumors. Using a mouse model, we studied the effects of sunitinib given for 4 weeks at concentrations comparable to 37.5–50 mg/day in humans, followed by 2 weeks off the drug (sunitinib 4/2). We assessed the effect of differently timed combinations of sunitinib and a poxvirus‐based vaccine encoding carcinoembryonic antigen (CEA) plus 3 costimulatory molecules on immune responses in CEA‐transgenic (CEA‐Tg) mice. Antitumor studies were performed in CEA‐Tg mice bearing CEA‐transfected MC38 murine colon carcinomas (MC38‐CEA), treated either concurrently or sequentially with sunitinib and vaccine. In vitro, sunitinib inhibited PDGFR phosphorylation on MC38‐CEA cells at concentrations similar to those biologically available during human treatment. In vivo, one cycle of sunitinib 4/2 caused bimodal immune effects: (a) decreased regulatory cells during the 4 weeks of treatment and (b) an immune‐suppression rebound during the 2 weeks of treatment interruption. In a model using CEA‐Tg mice bearing CEA+ tumors, continuous sunitinib followed by vaccine increased intratumoral infiltration of antigen‐specific T lymphocytes, decreased immunosuppressant T regulatory cells and myeloid‐derived suppressor cells, reduced tumor volumes and increased survival. The immunomodulatory activity of continuous sunitinib administration can create a more immune‐permissive environment. In combination with immunotherapies, sunitinib treatment should precede vaccine, to precondition the immune system, to maximize the response to vaccine‐mediated immune enhancement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ozao-Choy, J., Ma, G., Kao, J., Wang, G. X., Meseck, M., Sung, M., Schwartz, M., Divino, C. M., Pan, P.-Y., & Chen, S.-H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4709 · Cited by 538 · cited 2×
“1), sufficient to inhibit the same TKRs that are blocked during treatment in humans.21 A preclinical study by Ozao-Choy et al.24 showed that sunitinib in combination with an immunotherapeutic protocol (IL-12 and 4- 1BB activation) improved survival in MCA26 colon tumorbearing mice by reversal of intratumoral immune su…”
MethodFinke, J. H., Rini, B., Ireland, J., Rayman, P., Richmond, A., Golshayan, A., Wood, L., Elson, P., Garcia, J., Dreicer, R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5212 · Cited by 492 · cited 2×
“of reduced circulating immunosuppressive cells after 4 weeks of treatment in human patients.(9,10) Importantly, 4 weeks of sunitinib treatment affected mouse Tregs and MDSCs both quantitatively, by decreasing their numbers, and qualitatively, by inhibiting their ability to suppress T-cell proliferation (Figs.”
Background
Cited by
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
“…antigen and costimulatory molecules colon carcinoma [ intratumoral T cells Y MDSCs and Tregs Y tumor volume and [ survival (Farsaci et al., 2012) Sorafenib anti-PD-1 antibody with a CXCR4 inhibitor (AMD3100) hepatocellular carcinoma [ intratumoral T cells Y MDSCs and…”
Combining immunotherapy and targeted therapies in cancer treatment
Vanneman, M., & Dranoff, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3237 · Cited by 1,586
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099
“A previous study suggested that antiangiogenic therapy preceding vaccine therapy had a better anticancer effect than vaccine therapy followed by antiangiogenic treatment (37).”
BackgroundBracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Metadata
- Authors
- Farsaci, B., Higgins, J. P., & Hodge, J. W.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2011-08-08
- Volume
- 130
- Issue
- 8
- Pages
- 1948-1959
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2000884139
- Cited by
- 124
- References
- 2
- FWCI
- 7.45
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.